GlassScriptPhysician profile
Jill E Miller
NPI 1932370038
$32,191.82
in general payments reported to CMS, 2019-2025
20 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,085 · 2022: $3,795 · 2023: $4,124 · 2024: $5,492 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $4,624 · Travel and Lodging: $3,782 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,500 · Education: $23.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,382.50 |
| Food and Beverage | $4,624.10 |
| Travel and Lodging | $3,782.47 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,500.00 |
| Education | $23.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13,398.02 | 2021-2025 | |
| Adaptive Biotechnologies Corporation | $9,274.43 | 2021-2025 | Clonoseq |
| Lilly USA, LLC | $3,111.45 | 2024-2025 | Jaypirca |
| Pharmacyclics LLC, An Abbvie Company | $2,429.16 | 2021-2023 | Imbruvica, Epkinly |
| Astrazeneca Pharmaceuticals LP | $872.18 | 2022-2025 | Calquence |
| Janssen Biotech, INC. | $717.37 | 2021-2024 | Imbruvica |
| Tg Therapeutics, INC. | $630.00 | 2021 | |
| Astellas Pharma US INC | $543.99 | 2021-2024 | Cresemba, Xospata |
| Beigene USA, INC. | $382.20 | 2023-2024 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $128.06 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $126.86 | 2023 | Reblozyl |
| Celgene Corporation | $123.82 | 2022-2025 | Reblozyl, Breyanzi |
| Genentech, INC. | $115.77 | 2023 | Lunsumio, Polivy, Venclexta |
| Incyte Corporation | $113.25 | 2021-2024 | Jakafi |
| Sobi, INC | $100.71 | 2022-2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28.07 | 2025 | Ojjaara |
| Rigel Pharmaceuticals, INC. | $27.14 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Syndax Pharmaceuticals, INC. | $26.85 | 2025 | |
| Pfizer INC. | $23.69 | 2021 | |
| Invivyd INC | $18.80 | 2024 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.